Mostly Markets
Subscribe
Stocks/Health Care/Life Sciences Tools & Services

IQVIAIQV

Life Sciences Tools & Services · Durham, North Carolina · In the S&P 500
Solid business
$267.33−2.81%After hours: $267.33 (0.00%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 22.7% over 1 year
IQVIA over 1 yearDaily close, $, to 30 Oct 2026
$200$250Nov2026MarMayJulSep$267.33$200$250NovMarJul$267.33
Source: Nasdaq daily closes
Market value$44.06B
Price to earnings32.5x
Forward P/E19.8x
Dividend yield–
Year to date+18.6%
One year+22.7%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$156.66$279.36

Quality and valuation

How IQVIA compares with other health care stocks. A description, not a recommendation.

IQVIA and 7 life sciences tools & services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: in line with its sector

An average business among health care companies, priced about in line with them.

IQVIA trades at 19.8 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +8.8% vs +7.8%
  • Less profitable (operating margin): 12.8% vs 13.3%
  • Turns less of its sales into cash: 12.0% vs 15.9%
IQV trades at 19.8x forward earnings, above the sector medianForward p/e, Life Sciences Tools & Services peers
IQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1xIQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 32.5x earnings, IQV is pricier than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x25x30x35xAverage 26.1x2025202632.5x20x30xAverage 26.1x2025202632.5x
Source: Nasdaq prices; SEC filings

Financials

From IQVIA's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 8.0% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$4.4bnQ3 ’26$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$4.4bnQ3 ’26
Source: SEC filings
Growth slowed to +8.0% last quarterRevenue growth, year on year, %
0%5%10%Q4 ’24Q2 ’25Q4 ’258.0%Q3 ’260%5%10%Q4 ’24Q2 ’25Q4 ’258.0%Q3 ’26
Source: SEC filings
Operating margin was 12.9% last quarterOperating income as a share of revenue, %
0%5%10%15%Q4 ’24Q2 ’25Q4 ’2512.9%Q3 ’260%10%Q4 ’24Q2 ’25Q4 ’2512.9%Q3 ’26
Source: SEC filings
Free cash flow was $2.1 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400m$600mQ4 ’24Q2 ’25Q4 ’25$667mQ3 ’26$0m$500mQ4 ’24Q2 ’25Q4 ’25$667mQ3 ’26
Source: SEC filings
Last 12 monthsIQVSector median
Revenue growth+8.8%+7.8%
Operating margin12.8%13.3%
Free cash flow margin12.0%15.9%
Price to earnings32.5x30.2x

Stories on IQVIA

We haven't written about IQVIA yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Life Sciences Tools & Services, by market value.

CompanyPriceTodayYTDValue
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B
DHRDanaher$232.23−2.00%+1.4%$163B
AAgilent Technologies$174.87−3.47%+28.5%$49.30B
WATWaters$462.72−3.61%+21.8%$45.46B
ILMNIllumina$235.99−18.64%+79.9%$35.63B
MTDMettler Toledo$1,674.81−2.55%+20.1%$33.56B
CRLCharles River Laboratories$359.41−4.44%+80.2%$17.16B
TECHBio-Techne$72.66−0.07%+23.6%$11.41B